Cognoa develops AI-powered digital health tools designed to support the early identification and treatment of behavioral and neurodevelopmental conditions in children. The company’s flagship product, Canvas Dx, focuses on improving access to autism diagnosis through software-based assessment rather than in-person specialist evaluation alone. Its platform combines caregiver input, clinical data, and algorithmic analysis to support more timely and equitable diagnosis. Cognoa operates within regulated clinical and digital health frameworks.

The technology uses machine learning models trained on behavioral and developmental data to identify patterns associated with autism spectrum disorder. Canvas Dx integrates structured questionnaires, developmental history, and observational inputs to generate diagnostic support outputs for clinicians. The system is designed to reduce variability and delay in traditional diagnostic pathways by standardizing assessment inputs. This software-first approach emphasizes scalability and consistency across diverse populations and care settings.

Cognoa targets pediatric behavioral health, with an initial focus on autism diagnosis in young children. The platform is intended for use by clinicians and healthcare systems as part of formal diagnostic workflows. In parallel, the company is developing digital therapeutics aimed at supporting behavioral health and developmental outcomes, reflecting broader interest in software-based interventions within pediatric care.